| Literature DB >> 30170675 |
Robinder S Sidhu1, Benjamin D Tyrrell2, Robert C Welsh1, Steven R Meyer1, Miriam Shanks1, Kevin R Bainey3.
Abstract
Chronic mitral regurgitation (MR) remains a common cardiovascular condition resulting in significant morbidity and mortality. With an aging population, increasing trends for both primary (degenerative) and secondary (functional) MR have become apparent. Although the gold standard remains surgical intervention with mitral valve repair/replacement, comorbid conditions have steered the development of less invasive technologies to mitigate perioperative surgical risk. Transcatheter mitral valve repair using a percutaneous edge-to-edge technique is the most widely available choice at present. However, other transcatheter mitral valve repair techniques such as annuloplasty and chordal implantation are notable alternatives. Moreover, emerging technologies in transcatheter mitral valve replacement are rapidly establishing their roles in the field of chronic severe MR therapy. Hence, it is imperative to understand the indications and limitations of these various transcatheter mitral valve interventions to provide the best and most up-to-date clinical care for patients. This review will outline current evidence and patient selection criteria for such device-based therapies. CrownEntities:
Mesh:
Year: 2018 PMID: 30170675 DOI: 10.1016/j.cjca.2018.04.034
Source DB: PubMed Journal: Can J Cardiol ISSN: 0828-282X Impact factor: 5.223